Результаты поиска

Ex Vivo Treatment Response Prediction in Multiple Myeloma: Assay Formats, Clinical Correlation, and Future Directions.

Ex vivo functional testing for multiple myeloma is rapidly evolving, yet no single assay has reached the level of reliability and clinical utility needed for routine decision-making. Existing approaches generally fall into three categories: 2D cultures, 3D models, and dynamic systems. Each contributes valuable but incomplete insight into therapeutic response. Among these, 2D assays remain the most mature, with the most extensive clinical correlations to date, though their simplified architecture limits their ability to reflect the full complexity of the bone marrow microenvironment. However, 3

Совпадение в полном тексте источника
… Testing of melphalan and bortezomib within the model revealed distinct targets, with melphalan targeting the hematopoietic compartment while sparing the stromal compartment. Bortezomib was shown to target only CD138 and CD56 MM plasma cells. … The full list of drugs tested was carfilzomib, bortezomib, ixazomib, panobinostat, lenalidomide, pomalidomide, dexamethasone, etoposide, doxorubicin, daratumumab, and melphalan. …

Бремя лечения, секвенирования и использования ресурсов здравоохранения в множестве миеломы в Латинской Америке: обзор целевой литературы.

Утверждение основных классов лекарственных препаратов позволило улучшить выживание пациентов с множественной миеломой (ММ). В то же время большинство пациентов сталкиваются с рецидивом или становятся противниками этих методов лечения, причем повторное лечение имеет ограниченную эффективность. Доступ к этим основным методам лечения в разных странах Латинской Америки (ЛАТАМ), что может привести к неоптимальным клиническим результатам. Цель этого целевого обзора литературы заключалась в том, чтобы понять эпидемиологию, бремя лечения, последовательность лечения и наличие MM в Аргентине, Бразилии,

Совпадение в полном тексте источника
… Table 1 Patient characteristics ASCT autologous stem cell transplant, CTd cyclophosphamide, thalidomide, dexamethasone, Cy cyclophosphamide, CyBorD cyclophosphamide, bortezomib, dexamethasone, DRd daratumumab, lenalidomide, dexamethasone, D-VMP daratumumab, bortezomib, melphalan, prednisolone, G-CSF … Daratumumab plus bortezomib, melphalan, and prednisone versus standard of care in Latin America for transplant-ineligible newly diagnosed multiple myeloma: propensity score matching analysis. Adv Ther. 2020;37(12):4996–5009. 10.1007/s12325-020-01521-9. 103. …

The Landscape of lncRNAs in Multiple Myeloma: Implications in the "Hallmarks of Cancer", Clinical Perspectives and Therapeutic Opportunities.

Long non-coding RNAs (lncRNAs) are transcripts longer than 200 nucleotides that are not translated into proteins. Nowadays, lncRNAs are gaining importance as key regulators of gene expression and, consequently, of several biological functions in physiological and pathological conditions, including cancer. Here, we point out the role of lncRNAs in the pathogenesis of multiple myeloma (MM). We focus on their ability to regulate the biological processes identified as "hallmarks of cancer" that enable malignant cell transformation, early tumor onset and progression. The aberrant expression of lncR

Совпадение в полном тексте источника
… Furthermore, NEAT1 may also mediates resistance to melphalan, bortezomib and carfilzomib [ 28 ]. CRISPR-mediated deletion of CRNDE reduces MM cell growth and adhesion and increases sensitivity to dexamethasone. … Finally, linc00515 is overexpressed in melphalan-resistant MM cells and regulates chemoresistance by upregulating miR-140-5p and decreasing autophagy via the downregulation of ATG14 [ 127 ]. …

Perspectives on the Risk-Stratified Treatment of Multiple Myeloma.

The multiple myeloma treatment landscape has changed dramatically. This change, paralleled by an increase in scientific knowledge, has resulted in significant improvement in survival. However, heterogeneity remains in clinical outcomes, with a proportion of patients not benefiting from current approaches and continuing to have a poor prognosis. A significant proportion of the variability in outcome can be predicted on the basis of clinical and biochemical parameters and tumor-acquired genetic variants, allowing for risk stratification and a more personalized approach to therapy. This article d

Совпадение в полном тексте источника
… Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma . N Engl J Med 2018 ; 378 : 518 – 28 . 29231133 10.1056/NEJMoa1714678 83. Jackson GH , Davies FE , Pawlyn C , Cairns DA , Striha A , Collett C , . … Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM . Blood Adv 2020 ; 4 : 4834 – 7 . 33027527 10.1182/bloodadvances.2020002590 PMC7556152 94. Dimopoulos MA , Gay F , Schjesvold F , Beksac M , Hajek R , Weisel KC , . …

Лечение для пожилых пациентов из числа миеломы.

Замечательные успехи были достигнуты в лечении нескольких пациентов, страдающих миеломой (ММ); однако для слабых пожилых пациентов эти результаты лечения по-прежнему недостаточны. Увеличивается число пожилых пациентов с МР, равно как и число пациентов, проходящих курс лечения. Существует повышенный спрос на оценку этих пациентов в целях обеспечения оптимальных методов лечения. Несмотря на то, что непрерывное лечение чаще случается у пациентов с ОМ по сравнению с стационарным лечением, из-за риска прерывания лечения, что приводит к снижению показателей выживаемости, важное значение имеют эффект

Совпадение в полном тексте источника
… Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma N. Engl. J. Med. 2018 378 518 528 10.1056/NEJMoa1714678 29231133 34. Mian H. Wildes T.M. Vij R. Pianko M.J. Major A. Fiala M.A. … Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE Clin. Lymphoma Myeloma Leuk. 2021 21 785 798 10.1016/j.clml.2021.06.005 34344638 54. Stege C.A.M. …

The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Nurses Group - Poster Sessions (NP001 - NP054).

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Twenty-one patients (88%) received a conditioning regimen with high dose melphalan for multiple myeloma and 3 patients (22%) received BEAM conditioning for aggressive lymphoma. …

Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?

The introduction of high-dose therapy in the 1990s as well as the development of drugs such as thalidomide, lenalidomide, and bortezomib in the 2000s led to an impressive improvement in outcome of patients with multiple myeloma (MM) eligible for autologous stem cell transplantation (ASCT). Clinical trials conducted in the first ten years of the twenty-first century established as standard therapy for these patients a therapeutic approach including induction, single or double ASCT, consolidation, and maintenance therapy. More recently, incorporating second-generation proteasome inhibitors carfi

Совпадение в полном тексте источника
… Three cycles of VRD as induction were used in the phase III IFM 2009 study [ 17 ], whereas in the PETHEMA/GEM2012 study, patients received VRD for six cycles followed by ASCT conditioned with busulfan plus melphalan vs. melphalan. … Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: Results of a randomized controlled trial. Blood. 2004;104:3052–3057. doi: 10.1182/blood-2004-02-0408. 12. …

The 46th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Poster Session (P001-P706).

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Myeloablative conditioning regimen (MAC) based on busulfan (Bu) (10-16 mg/b.w.) received 105(92%) patients on treosulfan-9(8%) pts., reduced intensity conditioning (RIC) based on melphalan-37(63%) pts, based on Bu(8 mg/b.w.)-22(37%) pts. … In pts with hematological relapse at the time of HSCT Melphalan (Mel, 100mg/m 2 ) before Treo/Flu was added to induce aplasia. Immunosuppression consisted of ATG and Ciclosporin in combination with MTX or MMF. …

АнтиCD38 моноколональные антитела в множестве миеломы и за ее пределами: иммунотерапевтические механизмы, зрелость улик и клиническое позиционирование.

АнтиCD38 моноколональные антитела стали центральной иммунотерапевтической платформой во множестве миэломы, где они изменили курс лечения от рецидива или рефракторного заболевания, передней терапии, интенсификации технического обслуживания и минимального управления, ориентированного на остаточные заболевания. Их успех в многочисленных миеломах также стимулировал более широкое развитие в области иммуноглобулинового светового амилоида, отдельных гематологовых магнелез и юморальных иммунных расстройств. CD38 функционирует как как поверхностная мишень, так и как эктоэнзим, связанный с метаболизмом

Совпадение в полном тексте источника
… response; PR, partial response; R, lenalidomide; D-R, daratumumab plus lenalidomide; D-Rd, daratumumab plus lenalidomide and dexamethasone; D-VCd, daratumumab plus bortezomib, cyclophosphamide, and dexamethasone; D-Vd, daratumumab plus bortezomib and dexamethasone; D-VMP, daratumumab plus bortezomib, melphalan … ALCYONE showed that daratumumab also improved outcomes when added to bortezomib, melphalan, and prednisone, indicating that the value of CD38 targeting is not restricted to an immunomodulatory drug-based regimen ( 52 , 53 ). …

Концептуализация комплексного ухода за многими миеломами: роль питания, дополнительных услуг и дополнительных услуг.

Множественная миелома (ММ) — вторая по распространенности гематологическая гелингология, масштабы которой в последние годы значительно возросли. Прогноз ММ радикально изменился с введением новых лекарственных средств, повышающих ожидаемую продолжительность жизни; рецидивы являются обычным явлением во время болезни и характеризуются увеличением числа отказов от лечения. Кроме того, пациенты ММ сталкиваются с проблемами, связанными с качеством жизни, в то время как обычное лечение может быть ограничено. Это включает боль в костях и диализ из-за осложнений острой почечной недостаточности. Поэтому

Совпадение в полном тексте источника
… Moreover, it shows synergy with dexamethasone, doxorubicin, bortezomib, and melphalan. In in vivo models, it leads to a reduction in the burden of disease and an increase in survival [ 74 ]. … | Synergism with carfilzomib | [ 79 ] Sulforaphane | To be found | Synergism with dexamethasone, doxorubicin, bortezomib, and melphalan | [ 74 ] Resveratrol | To be found | Antagonism with bortezomib; possible side effects, not recommended | [ 75 , 76 ] 4. …

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.

BackgroundPatients with multiple myeloma treated with lenalidomide maintenance therapy have improved progression-free survival, primarily following autologous stem-cell transplantation. A beneficial effect of lenalidomide maintenance therapy on overall survival in this setting has been inconsistent between individual studies. Minimal data are available on the effect of maintenance lenalidomide in more aggressive disease states, such as patients with cytogenetic high-risk disease or patients ineligible for transplantation. We aimed to assess lenalidomide maintenance versus observation in patien

Совпадение в полном тексте источника
… For patients with multiple myeloma who are ineligible for transplantation, continuous therapy with lenalidomide plus low-dose dexamethasone improved progression-free survival and overall survival compared with a combination of melphalan, prednisone, and thalidomide. 19 , 20 No previous studies of either … Transplantation-eligible patients receiving KCRD proceeded to high-dose melphalan and autologous stem-cell transplantation. …

Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma.

Proteasome inhibition forms the cornerstone of antimyeloma therapy. The first-in-class proteasome inhibitor, bortezomib, either alone or in combination with other chemotherapeutic agents, induces high overall response rates and response qualities in patients with clinically and molecularly defined high-risk disease. However, resistance to bortezomib and neurotoxicity associated with the treatment remain challenging issues. Carfilzomib is a novel, well tolerated, irreversible proteasome inhibitor with minimal neurotoxicity. Carfilzomib demonstrates promising activity in myeloma patients who are

Совпадение в полном тексте источника
… Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma. Br J Haematol. 2009;144:887–894. doi: 10.1111/j.1365-2141.2008.07572.x. 64. Pineda-Roman M, Zangari M, van Rhee F, et al. … Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood. 2007;109:2767–2772. doi: 10.1182/blood-2006-08-042275. 73. Terpos E, Heath DJ, Zervas K, Dimopoulos MA. …

Case report: Light-chain amyloidosis responsive to selinexor in combination with daratumumab and dexamethasone (SDd) therapy.

The outcome of AL amyloidosis remains poor, particularly in patients with advanced organ involvement which takes long time to recovery. We conducted an observational study of two patients with AL amyloidosis treated with SDd regimen. Both patients successfully achieved significant hematological and organ responses without severe adverse events, and the time to organ response was remarkably shorter than previously reported. Notably, an over 15% reduction in interventricular septal thickness (IVST) was observed in patient#2 within 6 months. Up to now, SDd therapy has not been previously reported

Совпадение в полном тексте источника
… The use of drugs such as bortezomib, daratumumab, lenalidomide, melphalan and autologous hematopoietic stem cell transplantation has induced hematological and organ responses, and prolonged survival in patients with AL amyloidosis. … Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience. Blood. (2015) 126:2345–7. 10.1182/blood-2015-08-662726 12. de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, et al. …

Pomalidomide and Dexamethasone Are Effective in Relapsed or Refractory Multiple Myeloma in a Real-Life Setting: A Multicenter Retrospective Study in Taiwan.

BackgroundThe therapeutic options of relapsed or refractory multiple myeloma (RRMM) remain a challenge. The MM-003 trial demonstrated that RRMM patients treated with pomalidomide and dexamethasone (Pom/Dex) have better progression-free survival (PFS) than those treated with high-dose dexamethasone alone. However, the real-world effectiveness of Pom/Dex in these patients in Taiwan remains unclear.MethodsThis multicenter, registry-based study retrospectively reviewed the medical records of 49 consecutive patients undergoing Pom/Dex treatment for RRMM. We investigated the overall response rate (O

Совпадение в полном тексте источника
… In the VISTA trial, transplant-ineligible newly diagnosed MM patients undergoing induction therapy of bortezomib plus melphalan and prednisone were found to have better progression-free survival (PFS) and overall survival (OS) than those treated with melphalan and prednisolone ( 2 ). … Bortezomib Plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma. N Engl J Med (2008) 359(9):906–17. 10.1056/NEJMoa0801479 3. Cavo M, Pantani L, Pezzi A, Petrucci MT, Patriarca F, Di Raimondo F, et al. …

Successful Treatment of Relapsed/Refractory Extramedullary Multiple Myeloma With Anti-BCMA CAR-T Cell Therapy Followed by Haploidentical Hematopoietic Stem Cell Transplantation: A Case Report and a Review of the Contemporary Literature.

Extramedullary multiple myeloma (EMM) is an aggressive sub-entity of multiple myeloma (MM). Despite an excellent improvement in survival for most patients with MM over recent decades, the overall survival (OS) of patients with EMM was usually not longer than 3 years. Standard treatment for patients with EMM has not been established, and their management is particularly challenging. We presented a heavily pretreated young patient with relapsed EMM and refractoriness to a proteasome inhibitor (PI; bortezomib), a next-generation PI (ixazomib), immunomodulatory drugs (IMiDs; lenalidomide), autolog

Совпадение в полном тексте источника
… In September 2019, ASCT was performed after conditioning with melphalan (140 mg/m 2 ) and bortezomib (1 mg/m 2 four times). Thereafter, the right subpleural soft mass could no longer be detected. The patient received maintenance therapy with lenalidomide and bortezomib after transplantation. … Richardson recently reported the results of the phase II HORIZON trial with melphalan flufenamide (melflufen) in RRMM, which is a first-in-class peptide–drug conjugate that targets aminopeptidases and rapidly and selectively releases alkylating agents into tumor cells. …

Severe Oral Mucositis in Pediatric Cancer Patients: Survival Analysis and Predictive Factors.

This paper investigates the occurrence of severe oral mucositis and associated factors in blood and solid cancer pediatric patients subjected to cancer treatment, using a survival analysis. A longitudinal, descriptive, observational and inductive study of 142 pediatric patients aged from 0 to 19 years was conducted from 2013 to 2017. Data were collected using a form to record the sociodemographic characteristics and health-related aspects of patients and the modified Oral Assessment Guide (OAG). Survival analysis was performed using the Kaplan-Meier method and Cox semiparametric model. The med

Совпадение в полном тексте источника
… Many chemotherapeutic agents—such as epirubicin, cisplatin, paclitaxel, cyclophosphamide, and melphalan—are nephrotoxic and increase the serum creatinine and urea levels [ 37 , 38 ]. … Melphalan 180 Mg/M2 Can Be Safely Administered as Conditioning Regimen before an Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma Patients with Creatinine Clearance 60 ML/Min/1.73 M2 or Lower with Use of Palifermin for Cytoprotection: Results of a Phase I Trial Biol. …

Легочная артериальная сенсорная терапия для сердечно-сосудистого амилоидоза у молодого пациента с множественной миеломой.

ОКРУЖАЮЩАЯ СРЕДА: Оценка объема в сердечной амилоидной цепи освещения (AL) амилоидоз сопряжена с трудностями в ходе высокодозированной химиотерапии и аутологической трансплантации стволовых клеток, поскольку клинические результаты и вес тела могут не точно отражать внутриваскулярную загруженность. Резюме дела: A 45-year-old У человека с множественной миеломой, нефротическим синдромом и сердечным амилоидозом во время индуктивной терапии появились заметные колебания объема. Перед SCT был установлен имплантируемый датчик давления легочной артерии (PAP) для направления диуретиков. 22 мм Hg. В пери

Совпадение в полном тексте источника
… chemotherapy (daratumumab, bortezomib, cyclophosphamide, and dexamethasone). 8 mo Implantation of pulmonary artery pressure sensor. 8.5 mo CMR demonstrated myocardial fibrosis and edema, LVEF of 48% with increased end-systolic and end-diastolic volumes. 9 mo Peripheral stem cell collection. 10 mo High-dose melphalan … daratumumab, bortezomib, cyclophosphamide, and dexamethasone). 8 mo | Implantation of pulmonary artery pressure sensor. 8.5 mo | CMR demonstrated myocardial fibrosis and edema, LVEF of 48% with increased end-systolic and end-diastolic volumes. 9 mo | Peripheral stem cell collection. 10 mo | High-dose melphalan …

The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.

Ubiquitin Proteasome System (UPS) is an adaptable and finely tuned system that sustains proteostasis network under a large variety of physiopathological conditions. Its dysregulation is often associated with the onset and progression of human diseases; hence, UPS modulation has emerged as a promising new avenue for the development of treatments of several relevant pathologies, such as cancer and neurodegeneration. The clinical interest in proteasome inhibition has considerably increased after the FDA approval in 2003 of bortezomib for relapsed/refractory multiple myeloma, which is now used in

Predictors of Transplant Regret: A Case-Control Study Nested Within a Prospective Cohort of HSCT Recipients.

ObjectiveTo explore pre-hematopoietic stem cell transplant (HSCT) demographic, disease, and psychological factors predictive of future transplant regret and to determine post-HSCT variables associated with regret.Patients and methodsHSCT candidates participated in a prospective cohort study (June 2008-October 2013) examining health behaviors and HSCT outcomes, including completion of standardized surveys at pre-HSCT (baseline) and 1-year post-HSCT. Cases were participants that endorsed regret at 1-year post-HSCT follow-up, and controls were participants without regret at 1 year, matched on age

Совпадение в полном тексте источника
… Conditioning regimen was collapsed into three groups: BEAM, Melphalan, and Other. To explore group differences between those who endorsed regret and those who did not endorse transplant regret, conditional logistic regressions with 95% confidence intervals were performed. … ) | Amyloidosis | 1.04 (0.06–17.21) | 0.98 Multiple myeloma | 0.74 (0.05–10.41) | 0.82 Non‐Hodgkin lymphoma | 0.60 (0.04–8.08) | 0.70 Other | 0.68 (0.15–3.09) | 0.62 ECOG 0 | 1.00 (reference) | 1 | 1.22 (0.56–2.64) | 0.62 2 | 0.21 (0.02–1.90) | 0.16 Conditioning regimen BEAM | 1.00 (reference) | Melphalan …

Hematopoietic Stem Cell Transplant for Hematological Malignancies: Experience from a Tertiary Care Center in Northern India and Review of Indian Data.

Sanjeev Kumar SharmaHematopoietic stem cell transplantation (HSCT) is the preferred treatment for high-risk and relapsed/refractory hematological malignancies. Moreover, with the improved supportive care and increasing acceptance of haploidentical transplantations as an alternative treatment modality, more patients are opting for HSCT as a definite treatment for hematological malignancies. We report here the real-world data and outcome of HSCT done for hematological malignancies at our transplant center. Five hundred and sixteen patients underwent HSCT from August 2010 to November 2019. The mo

Совпадение в полном тексте источника
… the Consensus Center for International Blood and Marrow Transplant Research criteria. 1 Myeloablative conditioning (MAC) regimens were defined by busulfan (Bu) dose > 6.4 mg/kg intravenously, whereas reduced intensity conditioning (RIC) regimens were defined by Bu dose ≤ 6.4 mg/kg intravenously and melphalan … Haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide in children with advanced acute leukemia with fludarabine-, busulfan-, and melphalan-based conditioning. Biol Blood Marrow Transplant. 2016;22(03):499–504. doi: 10.1016/j.bbmt.2015.11.010. 22. …